Retour

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Stocks Earnings Releases and Operating Results

- Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 -

GlobeNewswire Inc. • 09/05/2024 à 13:45:00
Virios Therapeutics, Inc. Common Stock
Address: 44 MILTON AVENUE
Postal Code: 30009
City: ALPHARETTA
State: GA
Phone Number: (866) 620-8655
Website: https://www.virios.com
Status: Active
Company Info

Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia ("FM") and Long-COVID ("LC"). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.

List Date2020-12-17
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001818844
Composite figiBBG00X0SZKJ2
Share Class figiBBG00X0SZLB8
Market Cap6,767,239 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees4
Share Class Shares Outstanding19260000
Weighted Shares Outstanding19257937
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
0.243
0.42
0.399
0.448
0.351
Variance
-42.14%
7.14%
3.37%
27.64%
-3.57%
Open
0.42
0.392
0.386
0.351
0.364
Highest
0.42
0.42
0.435
0.455
0.376
Lowest
0.42
0.42
0.435
0.448
0.376
History
PeriodVarhighestlowest
1 week
-33.24%
0.376
0.376
1 month
-42.55%
0.441
0.376
3 month
-39.25%
0.446
0.345
6 month
-66.1%
0.754512
0.3316
1 year
-78.5%
1.14
0.3316
3 year
-95.55%
5.7
0.218951
5 year
-98%
16.71
0.218951
10 year
-98%
16.71
0.218951
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-12 2023-08-11 2023-11-13 UNPUB
Assets 6,520,617 5,212,119 5,248,905 UNPUB
Current Assets 6,520,617 5,212,119 5,248,905 UNPUB
Current Liabilities 549,290 520,032 487,144 UNPUB
Equity 5,971,327 4,692,087 4,761,761 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 5,971,327 4,692,087 4,761,761 UNPUB
Liabilities 549,290 520,032 487,144 UNPUB
Liabilities And Equity 6,520,617 5,212,119 5,248,905 UNPUB
Noncurrent Assets 0 0 0 UNPUB
Noncurrent Liabilities 0 0 0 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-12 2023-08-11 2023-11-13 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -1,698,450 -742,414 2,440,864 UNPUB
Net Cash Flow, Continuing -1,698,450 -742,414 2,440,864 UNPUB
Net Cash Flow From Financing Activities UNPUB UNPUB UNPUB UNPUB
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB UNPUB UNPUB
Net Cash Flow From Investing Activities UNPUB UNPUB UNPUB UNPUB
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB UNPUB UNPUB
Net Cash Flow From Operating Activities -1,698,450 -742,414 -960,454 UNPUB
Net Cash Flow From Operating Activities, Continuing -1,698,450 -742,414 -960,454 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-12 2023-08-11 2023-11-13 UNPUB
Comprehensive Income/Loss -1,516,864 -1,440,904 -1,235,074 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -1,516,864 -1,440,904 -1,235,074 UNPUB
Other Comprehensive Income/Loss 0 0 0 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-12 2023-08-11 2023-11-13 UNPUB
Basic Earnings Per Share 0 0 0 UNPUB
Benefits Costs and Expenses 1,557,287 1,477,217 1,274,289 UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 1,557,287 1,477,217 1,274,289 UNPUB
Diluted Earnings Per Share 0 0 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -1,516,864 -1,440,904 -1,235,074 UNPUB
Income/Loss From Continuing Operations Before Tax -1,516,864 -1,440,904 -1,235,074 UNPUB
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -1,516,864 -1,440,904 -1,235,074 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -1,516,864 -1,440,904 -1,235,074 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -1,516,864 -1,440,904 -1,235,074 UNPUB
Operating Expenses 1,557,287 1,477,217 1,274,289 UNPUB
Operating Income/Loss -1,557,287 -1,477,217 -1,274,289 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 40,423 36,313 39,215 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-13 2022-08-12 2022-11-14 2023-03-14
Assets 12,549,858 9,040,095 10,857,977 8,369,756
Current Assets 12,549,858 9,040,095 10,857,977 8,369,756
Current Liabilities 1,877,196 1,897,731 1,633,142 1,043,262
Equity 10,672,662 7,142,364 9,224,835 7,326,494
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 10,672,662 7,142,364 9,224,835 7,326,494
Liabilities 1,877,196 1,897,731 1,633,142 1,043,262
Liabilities And Equity 12,549,858 9,040,095 10,857,977 8,369,756
Noncurrent Assets 0 0 0 0
Noncurrent Liabilities 0 0 0 0
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-13 2022-08-12 2022-11-14 2023-03-14
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -2,656,017 -3,657,127 6,313,144 0
Net Cash Flow, Continuing -2,656,017 -3,657,127 6,313,144 0
Net Cash Flow From Financing Activities UNPUB UNPUB UNPUB 4,490,605
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB UNPUB 4,490,605
Net Cash Flow From Investing Activities UNPUB UNPUB UNPUB 6,977,192
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB UNPUB 6,977,192
Net Cash Flow From Operating Activities -2,656,017 -3,657,127 -2,483,243 -11,467,797
Net Cash Flow From Operating Activities, Continuing -2,656,017 -3,657,127 -2,483,243 -11,467,797
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-13 2022-08-12 2022-11-14 2023-03-14
Comprehensive Income/Loss -3,960,308 -3,667,255 -2,575,715 -12,247,834
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -3,960,308 -3,667,255 -2,575,715 -12,247,834
Other Comprehensive Income/Loss 0 0 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-13 2022-08-12 2022-11-14 2023-03-14
Basic Earnings Per Share 0 0 0 -1
Benefits Costs and Expenses 3,961,214 3,672,059 2,592,320 UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 3,961,214 3,672,059 2,592,320 UNPUB
Diluted Earnings Per Share 0 0 0 -1
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -3,960,308 -3,667,255 -2,575,715 -12,247,834
Income/Loss From Continuing Operations Before Tax -3,960,308 -3,667,255 -2,575,715 -12,247,834
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -3,960,308 -3,667,255 -2,575,715 -12,247,834
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -3,960,308 -3,667,255 -2,575,715 -12,247,834
Net Income/Loss Available To Common Stockholders, Basic -3,960,308 -3,667,255 -2,575,715 -12,247,834
Operating Expenses 3,961,214 3,672,059 2,592,320 12,315,309
Operating Income/Loss -3,961,214 -3,672,059 -2,592,320 -12,315,309
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 906 4,804 16,605 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-14 2021-08-13 2021-11-12 2022-03-18
Assets 28,274,537 23,764,782 20,107,236 15,776,687
Current Assets 28,274,537 23,764,782 20,107,236 15,776,687
Current Liabilities 1,167,294 906,257 1,226,787 1,275,623
Equity 27,107,243 22,858,525 18,880,449 14,501,064
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 27,107,243 22,858,525 18,880,449 14,501,064
Liabilities 1,167,294 906,257 1,226,787 1,275,623
Liabilities And Equity 28,274,537 23,764,782 20,107,236 15,776,687
Noncurrent Assets 0 0 0 0
Noncurrent Liabilities 0 0 0 0
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-14 2021-08-13 2021-11-12 2022-03-18
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 0 0 0
Net Cash Flow, Continuing 0 0 0 0
Net Cash Flow From Financing Activities -97,604 0 0 -97,604
Net Cash Flow From Financing Activities, Continuing -97,604 0 0 -97,604
Net Cash Flow From Investing Activities 5,209,806 2,750,468 2,648,768 15,787,182
Net Cash Flow From Investing Activities, Continuing 5,209,806 2,750,468 2,648,768 15,787,182
Net Cash Flow From Operating Activities -5,112,202 -2,750,468 -2,648,768 -15,689,578
Net Cash Flow From Operating Activities, Continuing -5,112,202 -2,750,468 -2,648,768 -15,689,578
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-14 2021-08-13 2021-11-12 2022-03-18
Comprehensive Income/Loss -3,056,033 -4,282,962 -4,109,982 -15,960,268
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -3,056,033 -4,282,962 -4,109,982 -15,960,268
Other Comprehensive Income/Loss 0 0 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-14 2021-08-13 2021-11-12 2022-03-18
Basic Earnings Per Share UNPUB UNPUB UNPUB -2
Benefits Costs and Expenses 3,057,433 4,284,457 4,111,491 UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 3,057,433 4,284,457 4,111,491 UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB -2
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -3,056,033 -4,282,962 -4,109,982 -15,960,268
Income/Loss From Continuing Operations Before Tax -3,056,033 -4,282,962 -4,109,982 -15,960,268
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -3,056,033 -4,282,962 -4,109,982 -15,960,268
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -3,056,033 -4,282,962 -4,109,982 -15,960,268
Net Income/Loss Available To Common Stockholders, Basic -3,056,033 -4,282,962 -4,109,982 -15,960,268
Operating Expenses 3,057,433 4,284,457 4,111,491 15,640,940
Operating Income/Loss -3,057,433 -4,284,457 -4,111,491 -15,640,940
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 1,400 1,495 1,509 0
Calendar
20 May 2024 (Time UTC) Actual Previous Consensus
★
10:30
United States
★★
09:00
United States
★★
09:00
United States
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-5400.000
-17800.000
★
15:30
United States
-66000.000
-60000.000
★
15:30
United States
59500.000
53700.000
★
15:30
United States
-116600.000
-135800.000
★★
15:30
United States
3200.000
4400.000
★
15:30
United States
203000.000
215400.000
★
15:30
United States
200.000
-31400.000
★
15:30
United States
61800.000
62600.000
★
15:30
United States
1300.000
1300.000
★
15:30
United States
-25300.000
-9700.000
★
15:30
United States
204500.000
199600.000
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:VIRI240517P00007500 OPASPS Put American 100 7.5 EMLD 2024-05-17
O:VIRI240517P00005000 OPASPS Put American 100 5 EMLD 2024-05-17
O:VIRI240517P00002500 OPASPS Put American 100 2.5 EMLD 2024-05-17
O:VIRI240517C00007500 OCASPS Call American 100 7.5 EMLD 2024-05-17
O:VIRI240517C00005000 OCASPS Call American 100 5 EMLD 2024-05-17
O:VIRI240517C00002500 OCASPS Call American 100 2.5 EMLD 2024-05-17
O:VIRI240419P00007500 OPASPS Put American 100 7.5 EMLD 2024-04-19
O:VIRI240419P00005000 OPASPS Put American 100 5 EMLD 2024-04-19
O:VIRI240419P00002500 OPASPS Put American 100 2.5 EMLD 2024-04-19
O:VIRI240419C00007500 OCASPS Call American 100 7.5 EMLD 2024-04-19
O:VIRI240419C00005000 OCASPS Call American 100 5 EMLD 2024-04-19
O:VIRI240419C00002500 OCASPS Call American 100 2.5 EMLD 2024-04-19
O:VIRI240315P00007500 OPASPS Put American 100 7.5 EMLD 2024-03-15
O:VIRI240315P00005000 OPASPS Put American 100 5 EMLD 2024-03-15
O:VIRI240315P00002500 OPASPS Put American 100 2.5 EMLD 2024-03-15
O:VIRI240315C00007500 OCASPS Call American 100 7.5 EMLD 2024-03-15
O:VIRI240315C00005000 OCASPS Call American 100 5 EMLD 2024-03-15
O:VIRI240315C00002500 OCASPS Call American 100 2.5 EMLD 2024-03-15
O:VIRI240216P00007500 OPASPS Put American 100 7.5 EMLD 2024-02-16
O:VIRI240216P00005000 OPASPS Put American 100 5 EMLD 2024-02-16
O:VIRI240216P00002500 OPASPS Put American 100 2.5 EMLD 2024-02-16
O:VIRI240216C00007500 OCASPS Call American 100 7.5 EMLD 2024-02-16
O:VIRI240216C00005000 OCASPS Call American 100 5 EMLD 2024-02-16
O:VIRI240216C00002500 OCASPS Call American 100 2.5 EMLD 2024-02-16
O:VIRI240119P00007500 OPASPS Put American 100 7.5 EMLD 2024-01-19
O:VIRI240119P00005000 OPASPS Put American 100 5 EMLD 2024-01-19
O:VIRI240119P00002500 OPASPS Put American 100 2.5 EMLD 2024-01-19
O:VIRI240119C00007500 OCASPS Call American 100 7.5 EMLD 2024-01-19
O:VIRI240119C00005000 OCASPS Call American 100 5 EMLD 2024-01-19
O:VIRI240119C00002500 OCASPS Call American 100 2.5 EMLD 2024-01-19
O:VIRI231215P00007500 OPASPS Put American 100 7.5 EMLD 2023-12-15
O:VIRI231215P00005000 OPASPS Put American 100 5 EMLD 2023-12-15
O:VIRI231215P00002500 OPASPS Put American 100 2.5 EMLD 2023-12-15
O:VIRI231215C00007500 OCASPS Call American 100 7.5 EMLD 2023-12-15
O:VIRI231215C00005000 OCASPS Call American 100 5 EMLD 2023-12-15
O:VIRI231215C00002500 OCASPS Call American 100 2.5 EMLD 2023-12-15
O:VIRI231117P00007500 OPASPS Put American 100 7.5 EMLD 2023-11-17
O:VIRI231117P00005000 OPASPS Put American 100 5 EMLD 2023-11-17
O:VIRI231117P00002500 OPASPS Put American 100 2.5 EMLD 2023-11-17
O:VIRI231117C00007500 OCASPS Call American 100 7.5 EMLD 2023-11-17
O:VIRI231117C00005000 OCASPS Call American 100 5 EMLD 2023-11-17
O:VIRI231117C00002500 OCASPS Call American 100 2.5 EMLD 2023-11-17
O:VIRI231020P00007500 OPASPS Put American 100 7.5 EMLD 2023-10-20
O:VIRI231020P00005000 OPASPS Put American 100 5 EMLD 2023-10-20
O:VIRI231020P00002500 OPASPS Put American 100 2.5 EMLD 2023-10-20
O:VIRI231020C00007500 OCASPS Call American 100 7.5 EMLD 2023-10-20
O:VIRI231020C00005000 OCASPS Call American 100 5 EMLD 2023-10-20
O:VIRI231020C00002500 OCASPS Call American 100 2.5 EMLD 2023-10-20
O:VIRI230915P00007500 OPASPS Put American 100 7.5 EMLD 2023-09-15
O:VIRI230915P00005000 OPASPS Put American 100 5 EMLD 2023-09-15
O:VIRI230915P00002500 OPASPS Put American 100 2.5 EMLD 2023-09-15
O:VIRI230915C00007500 OCASPS Call American 100 7.5 EMLD 2023-09-15
O:VIRI230915C00005000 OCASPS Call American 100 5 EMLD 2023-09-15
O:VIRI230915C00002500 OCASPS Call American 100 2.5 EMLD 2023-09-15
O:VIRI230818P00007500 OPASPS Put American 100 7.5 EMLD 2023-08-18
O:VIRI230818P00005000 OPASPS Put American 100 5 EMLD 2023-08-18
O:VIRI230818P00002500 OPASPS Put American 100 2.5 EMLD 2023-08-18
O:VIRI230818C00007500 OCASPS Call American 100 7.5 EMLD 2023-08-18
O:VIRI230818C00005000 OCASPS Call American 100 5 EMLD 2023-08-18
O:VIRI230818C00002500 OCASPS Call American 100 2.5 EMLD 2023-08-18
News Stream
Stocks Financing Agreements
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
ATLANTA, May 17, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced that it intends to offer and sell up to $2.1 million in shares of its common stock in a public offering. All shares of common stock in the offering are to be offered by Virios Therapeutics. Virios Therapeutics intends to use the net proceeds of the proposed offering to commence preparatory activities for its planned IMC-2 Long-COVID Phase 2b study and for general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
GlobeNewswire Inc. • 2d ago
Stocks Earnings Releases and Operating Results
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
- Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 -
GlobeNewswire Inc. • 1w ago
News Conference Calls/ Webcasts
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that it will report first quarter 2024 financial results on Thursday, May 9, 2024 before the open of the financial markets. Management will also host a webcast and conference call on May 9, 2024 at 8:30 a.m. ET to discuss the results and provide a corporate update.
GlobeNewswire Inc. • 2w ago
stocks Health
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
- New patent would extend coverage and expand potential value of Virios’ antiviral pipeline globally –
GlobeNewswire Inc. • 1mo ago
Health Health
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
- New patent would extend coverage and expand potential value of Virios’ antiviral pipeline globally –
GlobeNewswire Inc. • 1mo ago
Stocks Earnings Releases and Operating Results
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the fourth quarter and full year ended December 31, 2023.
GlobeNewswire Inc. • 2mo ago
Stocks Major shareholder announcements
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
ATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today issued a Shareholder Letter highlighting the Company’s progress and key milestones in 2024.
GlobeNewswire Inc. • 2mo ago
Health Health
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
- Placebo-Controlled Clinical Proof of Concept Data Expected in Mid-2024 -- Targeting Initiation of IMC-2 Phase 2 program in 2H 2024 -
GlobeNewswire Inc. • 3mo ago
News Product / Services Announcement
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on developing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced receipt of the Food and Drug Administration’s (“FDA”) feedback on requirements for advancing IMC-2 (combination of valacyclovir + celecoxib) as a treatment for the fatigue, orthostatic intolerance and other symptoms associated with LC illness, also known as post-acute sequelae of SARS-CoV-2 infection (“PASC”).
GlobeNewswire Inc. • 4mo ago
Stocks Earnings Releases and Operating Results
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- Conference Call Today at 8:30 a.m. ET -
GlobeNewswire Inc. • 6mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT